The correct approach to community-acquired pneumonia in immunocompetent adults: Review of current guidelines

New Microbiologica

Volumn 31, Issue 1, 2008, Pages 1-18

  Carbonara, Sergio ^a,b   Stano, Francesca ^a   Scotto, Gaetano ^b   Monno, Laura ^a   Angarano, Gioacchino ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Community acquired; Guidelines; Pneumonia

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT;

AGED; ANTIBIOTIC RESISTANCE; ANTIVIRAL RESISTANCE; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOCOMPETENCE; MALE; MICROBIOLOGY; MIDDLE AGED; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; VIROLOGY; VIRUS PNEUMONIA;

AGED; ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, VIRAL; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOCOMPETENCE; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 41049109376     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. ALIKHAN R., COHEN A.T., COMBE S., ET AL. (2004). Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch. Intern. Med. 164, 963-968.
2. ANGUS D.C., MARRIE T.J., OBROSKY D.S., ET AL. (2002). Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am. J. Respir. Crit. Care. Med. 166, 717-723.
3. ARANCIBIA F., BAUER T.T., EWIG S., ET AL. (2002). Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch. Intern. Med. 162, 1849-1858.
4. ARANCIBIA F., EWIG S., MARTINEZ JA., ET AL. (2000). Antimicrobial treatment failures in patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 162, 154-160.
5. BARTLETT J.G. (1977). Diagnostic accuracy of transtracheal aspiration bacteriologic studies. Am. Rev. Respir. Dis. 115, 777-782.
6. BARTLETT J.G., DOWELL S.F., MANDELL L.A., ET AL. (2000). Guidelines from the Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 31, 347-382.
7. BELLEI N., BENFICA D., PEROSA A.H., CARLUCCI R., BARROS M., GRANATO C. (2003). Evaluation of a rapid test (QuickVue) compared with the shell vial assay for detection of influenza virus clearance after antiviral treatment. J. Virol. Methods 109, 85-88.
8. BRITISH THORACIC SOCIETY (BTS) PNEUMONIA GUIDELINES COMMITTEE. (2004 update). BTS guidelines for the management of community acquired pneumonia in adults. Published online on the BTS website www.brit-thoracic.org.uk/ on 30 Apr 2004.
9. CAMPBELL S.G., MARRIE T.J., ANSTEY R., DICKINSON G., ACKROYD-STOLARZ S. (2003). The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest. 123, 1142.
10. CANTRAL D.E., TAPE T.G., REED E.G., SPURZEM J.R., RENNARD S.I., THOMPSON A.B. (1993). Quantitative culture of bronchoalveolar lavage fluid for the diagnosis of bacterial pneumonia. Am. J. Med. 95, 601-607.
11. CAPELASTEGUI A., ESPANA P.P., QUINTANA J.M., ET AL. (2004). Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before and after design study. Clin. Infect. Dis. 39, 955-963.
12. CAPELASTEGUI A., ESPANA P.P., QUINTANA J.M., ET AL. (2006). Validation of a predictive rule for the management of community-acquired pneumonia. Eur. Respir. J. 27, 151-157.
13. CARRATALA J., FERNANDEZ-SABE N., ORTEGA L., ET AL. (2005). Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Ann. Intern. Med. 142, 165-172.
14. CHAN K.H., MALDEIS N., POPE W., ET AL. (2002). Evaluation of the Directigen FluA+B test for rapid diagnosis of influenza virus type A and B infections. J. Clin. Microbiol. 40, 1675-1680.
15. CLAY K.D., HANSON J.S., POPE S.D., RISSMILLER R.W., PURDUM P.P. III, BANKS P.M. (2006). Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann. Intern. Med. 144, 415-420.
16. DAVIDSON R., CAVALCANTI R., BRUNTON J.L., ET AL. (2002). Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346, 747-750.
17. DEAN N.C., SILVER M.P., BATEMAN K.A., JAMES B., HADLOCK C.J., HALE D. (2001). Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am. J. Med. 110: 451-457.
18. DEAN N.C., SUCHYTA M.R., BATEMAN K.A., ARONSKY D., HADLOCK C.J. (2000). Implementation of admission decision support for community-acquired pneumonia. Chest. 117, 1368-1377.
19. DERESINSKI S. (2005). Methicillin-resistant S. aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40, 562-573.
20. DOMINGUEZ J., GALI N., BLANCO S., ET AL. (2001). Detection of S. pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest. 119, 243-249.
21. DUNBAR L.M., WUNDERINK R.G., HABIB M.P., ET AL. (2003). High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37, 752-760.
22. EUROPEAN ANTIMICROBIAL RESISTANCE SURVEILLANCE SYSTEM (EARSS). Annual report, 2005, available on line at the website http://www.rivm.nl/earss
23. FELMINGHAM D. (2002) Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. J. Infection. 44 (suppl A), 3-1.
24. FILE T.M. JR. (2003). Community acquired Pneumoniae. Lancet 362, 1991-2001.
25. FILE T.M. JR, GARAU J., BLASI F., ET AL. (2004). Guidelines for empiric antimicrobial prescribing in community - acquired pneumonia. Chest. 125, 1888-1901.
26. FILE T.M. JR, PLOUFFE J.F. JR, BREIMAN R.F., SKELTON S.K. (1999). Clinical characteristics of Chlamydia pneumoniae infection as the sole cause of community-acquired pneumonia. Clin. Infect. Dis. 29, 426-428.
27. FINE M.J., AUBLE T.E., YEALY D.M., ET AL. (1997). A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336, 243-250.
28. FINE M.J., STONE R.A., LAVE J.R., ET AL. (2003). Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community acquired pneumonia: a randomized controlled trial. Am. J. Med. 115, 343-351.
29. FOGARTY C., SIAMI G., KOHLER R., ET AL. (2004). Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin. Infect. Dis. 38 (suppl), S16-S23.
30. GARCIA-VAZQUEZ E., MARCOS M.A., MENSA J., ET AL. (2004). Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch. Intern. Med. 164, 1807-1811.
31. GORAK E.J., YAMADA S.M., BROWN J.D. (1999). Community-acquired methicillinresistant S. aureus in hospitalized adults and children without known risk factors. Clin. Infect. Dis. 29, 797-800.
32. GUTIERREZ F., MASIA M., RODRIGUEZ J.C., ET AL. (2003). Evaluation of the immunochromatographic Binax NOW assay for detection of S. pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin. Infect. Dis. 36, 286-292.
33. HAGBERG L., CARBON C., VAN RENSBURG D J., FOGARTY C., DUNBAR L., PULLMAN J. (2003). Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. Respir. Med. 97, 625-633.
34. HALM E.A., FINE M.J., KAPOOR W.N., SINGER D.E., MARRIE T.J., SIU A.L. (2002). Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch. Intern. Med. 162, 1278-1284.
35. HALM E.A., FINE M.J., MARRIE T.J., ET AL. (1998). Time to clinical stability in patients hospitalized with communityacquired pneumonia: implications for practice guidelines. JAMA 279, 1452-1457.
36. HELBIG J.H., ULDUM S.A., LUCK P.C., HARRISON T.G. (2001). Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J. Med. Microbiol. 50, 509-516.
37. HO P.L., TSE W.S., TSANG K.W., ET AL. (2001). Risk factors for acquisition of levofloxacin-resistant S. pneumoniae: a case-control study. Clin. Infect. Dis. 32, 701-707.
38. HOUCK P.M., BRATZLER D.W., NSA W., MA A., BARTLETT J.G. (2004). Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 164, 637-644.
39. HYDE T.B., GAY K., STEPHENS D.S., ET AL. (2001). Macrolide resistance among invasive S. pneumoniae isolates. JAMA 286, 1857-1862.
40. SHIDA T., HASHIMOTO T., ARITA M., ET AL. (2001). Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern. Med. 40, 873-877.
41. JACOBS M.R., FELMINGHAM D., APPELBAUM P.C., GRUNEBERG R.N. AND THE ALEXANDER PROJECT GROUP (2003). The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired lower respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52, 229-246.
42. JIMENEZ P., SALDIAS F., MENESES M., SILVA M.E., WILSON M.G., OTTH L. (1993). Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia: comparison between bronchoalveolar lavage and telescoping plugged catheter cultures. Chest. 103, 1023-1027.
43. KLUGMAN K.P., LOW K.P., METLAY J., PECHEREE J.C., WEISS K. (2004). Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities. Review. International Journal of Antimicrobial Agents 24, 411-422.
44. KOLLEF M.H., SHERMAN G., WARD S., FRASER V.J. (1999). Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 115, 462-474.
45. LANDRY M.L., COHEN S., FERGUSON D. (2004). Comparison of Binax NOW and Directigen for rapid detection of influenza A and B. J. Clin. Virol. 31, 113-115.
46. LIEBERMAN D., SCHLAEFFER F., BOLDUR I., ET AL. (1996). Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 51, 179-184.
47. LIM W.S., VAN DER EERDEN M.M., LAING R., ET AL. (2003). Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 58, 377-382.
48. LONKS J.R., GARAU J., GOMEZ L., ET AL. (2002). Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant S. pneumoniae. Clin. Infect. Dis. 35, 556-564.
49. MANDELL L.A., WUNDERICK R.G., ANZUETO A., ET AL. (2007). Infectious Diseases Society of America/America Thoracic Society. Consensus guidelines on the management of community acquired pneumonia in adults. Clin. Infect. Dis. 44 (Suppl 2).
50. MARRIE T.J., LAU C.Y., WHEELER S.L., WONG C.J., VANDERVOORT M.K., FEAGAN B.C. (2000). A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 283, 749-755.
51. METERSKY M.L., MA A., BRATZLER D.W., HOUCK P.M. (2004). Predicting bacteremia in patients with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 169, 342-347.
52. MORTENSEN E.M., RESTREPO M., ANZUETO A., PUGH J. (2004). Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am. J. Med. 117, 726-731.
53. MURDOCH D.R., LAING R.T., COOK J.M. (2003). The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD. Clin. Infect. Dis. 37, 153-154.
54. MURDOCH D.R., LAING R.T., MILLS G.D., ET AL. (2001). Evaluation of a rapid immunochromatographic test for detection of S. pneumoniae antigen in urine samples from adults with community-acquiredpneumonia. J. Clin. Microbiol. 39, 3495-3498.
55. MUSHER D.M., MONTOYA R., WANAHITA A. (2004). Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 39, 165-169.
56. NAVARRO D., GARCIA-MASET L., GIMENO C., ESCRIBANO A., GARCIA-DE-LOMAS J. (2004). Performance of the Binax NOW S. pneumoniae urinary antigen assay for diagnosis of pneumonia in children with underlying pulmonary diseases in the absence of acute pneumococcal infection. J. Clin. Microbiol. 42, 4853-4855.
57. NIEDERMAN M.S., MANDELL L.A., ANZUETO A., ET AL. (2001). Guidelines for the management of adults with Community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163, 1730-1754.
58. NIEDERMAN M.S., MCCOMBS J.S., UNGER A.N., KUMAR A., POPOVIAN R. (1998). The cost of treating community-acquired pneumonia. Clin. Ther. 20, 820-837.
59. PAGANIN F., LILIENTHAL F., BOURDIN A., ET AL. (2004). Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur. Respir. J. 24, 779-785.
60. RASMUSSEN T.R., KORSGAARD J., MOLLER J.K., SOMMER T., KILIAN M. (2001). Quantitative culture of bronchoalveolar lavage fluid in community-acquired lower respiratory tract infections. Respir. Med. 95, 885-890.
61. ROSON B., CARRATALA J., FERNANDEZ-S ABE N., TUBAU F., MANRESA F., GUDIOL F. (2004). Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch. Intern. Med. 164, 502-508.
62. ROSON B., CARRATALA J., VERDAGUER R., DORCA J., MANRESA F., GUDIOL F. (2000). Prospective study of the usefulness of sputum Gram stain in the initial approach to communityacquired pneumonia requiring hospitalization. Clin. Infect. Dis. 31, 869-874.
63. ROSON B., FERNANDEZ-SABE N., CARRATALA J., ET AL. (2004). Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin. Infect. Dis. 38, 222-226.
64. RUHE J.J., HASBUN R. (2003). S. pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin. Infect. Dis. 36, 1132-1138.
65. RUIZ M., EWIG S., MARCOS M.A., ET AL. (1999 ). Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am. J. Respir. Crit. Care Med. 160, 397-405.
66. SCOTT J.A., HALL A.J. (1999). The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia. Chest. 116, 1716-1732.
67. SEGRETI J., HOUSE H.R., SIEGEL R.E. (2005). Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am. J. Med. 118 (Suppl. 1), 21-28.
68. SHEFET D., ROBENSHTOK E., PAUL M., LEIBOVICI L. (2005). Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch. Intern. Med. 165, 1992-2000.
69. SHETTY A.K., TREYNOR E., HILL D.W., GUTIERREZ K.M., WARFORD A., BARON E.J. (2003). Comparison of conventional viral cultures with direct fluorescent antibody stains for diagnosis of community-acquired respiratory virus infections in hospitalized children. Pediatr. Infect. Dis. J. 22, 789-794.
70. SIMPSON J.C., MACFARLANE J.T., WATSON J., WOODHEAD M.A. (2000). A national confidential enquiry into community-acquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Research Committee and Public Health Laboratory Service. Thorax. 55, 1040-1045.
71. SKERRETT S.J. (1999). Diagnostic testing for community-acquired pneumonia. Clin. Chest. Med. 20, 531-548.
72. SUCHYTA M.R., DEAN N.C., NARUS S., HADLOCK C.J. (2001). Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am. J. Med. 110, 306-309.
73. TEMPLETON K.E., SCHELTINGA S.A., VAN DEN EEDEN W.C., GRAFFELMAN A.W., VAN DEN BROEK P.J., CLAAS E.C. (2005). Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin. Infect. Dis. 41, 345-351.
74. VENEZIA R.A., DOMARACKI B.E., EVANS A.M., PRESTON K.E., GRAFFUNDER E.M. (2001). Selection of high-level oxacillin resistance in heteroresistant S. aureus by fluoroquinolone exposure. J. Antimicrob. Chemother. 48, 375-381.
75. WATERER G.W., WUNDERINK R.G. (2001). The influence of the severity of community- acquired pneumonia on the usefulness of blood cultures. Respir. Med. 95, 78-82.
76. WIPF J.E., LIPSKY B.A., HIRSCHMANN J.V., ET AL. (1999). Diagnosing pneumonia by physical examination: relevant or relic? Arch. Intern. Med. 159, 1082-1087.
77. WOODHEAD M. (2002). Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur. Respir. J 20, 20S-27S.
78. WOODHEAD M., BLASI F., EWIG S., ET AL. (2005). European Respiratory Society Task Force in collaboration with the European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26 (suppl 6), 1138-1180.
79. YU V.L., CHIOU C.C., FELDMAN C., ET AL. (2003). An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin. Infect. Dis. 37, 230-237.